Sarah Kiely | IR |
Mark Enyedy | President, CEO & Director |
Anna Berkenblit | VP & Chief Medical Officer |
David Johnston | EVP & CFO |
Richard Gregory | EVP & Chief Scientific Officer |
Biren Amin | Jefferies |
John Newman | Canaccord Genuity Limited |
Boris Peaker | Cowen and Company |
Jessica Fye | JPMorgan Chase & Co. |
Kennen MacKay | RBC Capital Markets |
Earl DeSouza | H.C. Wainwright & Co. |
Andy Hsieh | William Blair & Company |
Good day, and welcome, everyone, to this ImmunoGen Second Quarter 2018 Financial Results Conference Call. Today's call is being recorded. At this time, for opening remarks and introductions, I would like to turn the call over to Sarah Kiely, Investor Relations and Corporate Communications. Please go ahead, ma'am.
Good morning, and thank you for joining today's call.